Autor: "Buchan NC" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Managing advanced prostate cancer in the Asia Pacific region: "Real-world" application of Advanced Prostate Cancer Consensus Conference 2019 statements.
Autorzy:: Chiong E; Department of Urology, National University Hospital, National University Health System, Singapore.; Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Murphy DG; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
Buchan NC; Department of Urology, Christchurch Hospital, Christchurch, New Zealand.
Chua MLK; Divisions of Radiation Oncology and Medical Sciences, National Cancer Centre Singapore, Singapore.; Oncology Academic Programme, Duke-NUS Medical School, Singapore.
Hakim L; Department of Urology, Faculty of Medicine, Airlangga University/Airlangga University Hospital, Surabaya, Indonesia.
Hamid AR; Department of Urology, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
Hong SK; Department of Urology, Seoul National University Bundang Hospital, Seongnam-si, Korea.
Horvath LG; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, New South Wales, Australia.
Kanesvaran R; Oncology Academic Programme, Duke-NUS Medical School, Singapore.; Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
Khochikar M; Department of Uro-oncology, Siddhi Vinayak Ganapati Cancer Hospital, Miraj, India.
Letran J; Section of Urology, Chinese General Hospital and Medical Center, Manila, Philippines.
Lojanapiwat B; Division of Urology, Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Malek R; Department of Urology, Selayang Hospital, Kuala Lumpur, Malaysia.
Ng ACF; SH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.
Vinh NT; Department of Urology, Binh dan Hospital, Ho Chi Minh City, Vietnam.
Pang ST; Department of Urology, Chang Gung Memorial Hospital Linkou, Taoyuan, Taiwan.
Poon DMC; Department of Clinical Oncology, The Chinese University of Hong Kong, Shatin, Hong Kong.
Ong TA; Division of Urology, Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Saad M; Department of Clinical Oncology, University of Malaya Medical Centre, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Schubach K; Men's Health Melbourne, Melbourne, Victoria, Australia.; Australian and New Zealand Urology Nurses Society (ANZUNS), Australia.; ANZUP Cancer Trials Group, Sydney, New South Wales, Australia.
Shiroki R; Department of Urology, Fujita Health University, Nagoya, Japan.
Türkeri L; Department of Urology, Acıbadem M.A. Aydınlar University, Istanbul, Turkey.
Williams S; Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Wong A; Department of Haematology Oncology, National University Hospital, Singapore.
Ye D; Department of Urology, Shanghai Cancer Center, Shanghai, China.
Davis ID; ANZUP Cancer Trials Group, Sydney, New South Wales, Australia.; Monash University, Melbourne, Victoria, Australia.; Eastern Health, Melbourne, Victoria, Australia.; Pokaż więcej
Corporate Authors:: ANZUP Cancer Trials Group; ANZUP Cancer Trials Group, Sydney, New South Wales, Australia.
Źródło:: Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2022 Dec; Vol. 18 (6), pp. 686-695. Date of Electronic Publication: 2022 Feb 08.
Typ publikacji:: Journal Article
MeSH Terms:: COVID-19*/epidemiology
Prostatic Neoplasms*/diagnostic imaging
Prostatic Neoplasms*/epidemiology
Male ; Humans ; Positron Emission Tomography Computed Tomography ; Pandemics ; Asia/epidemiology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Management of patients with advanced prostate cancer in the Asia Pacific region: 'real-world' consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017.
Autorzy:: Chiong E; Department of Urology, National University Hospital, National University Health System Singapore, Singapore City, Singapore.
Murphy DG; Division of Cancer Surgery, Peter MacCallum Cancer Centre Melbourne, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.
Akaza H; Strategic Investigation on Comprehensive Cancer Network, The University of Tokyo, Tokyo, Japan.
Buchan NC; Canterbury Urology Research Trust, Christchurch, New Zealand.; Canterbury District Health Board, Christchurch, New Zealand.
Chung BH; Department of Urology, Yonsei University College of Medicine, Seoul, Korea.
Kanesvaran R; Division of Medical Oncology, National Cancer Centre Singapore, Singapore City, Singapore.
Khochikar M; Siddhi Vinayak Ganapati Cancer Hospital, Miraj, India.
Letran J; Section of Urology, Department of Surgery, University of Santo Tomas, Manila, Philippines.
Lojanapiwat B; Division of Urology, Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Ng CF; Department of Surgery, SH Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China.
Ong T; Division of Urology, Department of Surgery, University of Malaya, Kuala Lumpur, Malaysia.
Pu YS; Department of Urology, National Taiwan University Hospital, Taipei, Taiwan.
Saad M; Department of Clinical Oncology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Schubach K; Australian and New Zealand Urology Nurses (ANZUNS), Melbourne, VIC, Australia.
Türkeri L; Department of Urology, Acıbadem University, Istanbul, Turkey.
Umbas R; Department of Urology, University of Indonesia, Jakarta, Indonesia.
Le Chuyen V; Department of Urology, Binh dan Hospital, Ho Chi Minh City, Vietnam.
Williams S; Division of Radiation Oncology, Peter MacCallum Cancer Centre Melbourne, Melbourne, VIC, Australia.; ANZUP Cancer Trials Group, Sydney, NSW, Australia.
Ye DW; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Davis ID; Monash University, Melbourne, VIC, Australia.; Eastern Health, Melbourne, VIC, Australia.; ANZUP Cancer Trials Group, Sydney, NSW, Australia.; Pokaż więcej
Corporate Authors:: ANZUP Cancer Trials Group; Lifehouse, Camperdown, Sydney, NSW, Australia.
Źródło:: BJU international [BJU Int] 2019 Jan; Vol. 123 (1), pp. 22-34. Date of Electronic Publication: 2018 Aug 19.
Typ publikacji:: Consensus Development Conference; Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms:: Developing Countries*
Prostatic Neoplasms/*pathology
Prostatic Neoplasms/*therapy
Androgen Antagonists/therapeutic use ; Androstenes/therapeutic use ; Antineoplastic Agents/economics ; Antineoplastic Agents/supply & distribution ; Antineoplastic Agents/therapeutic use ; Asia, Southeastern ; Combined Modality Therapy ; Consensus ; Docetaxel/therapeutic use ; Asia, Eastern ; Humans ; Lymph Node Excision ; Male ; Neoplasm Metastasis ; Oceania ; Prostatectomy ; Radiotherapy ; Risk Factors

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Buchan NC"" wg kryterium: Autor

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język